Latest The City of London Migraine Clinic Stories
NeurAxon, a developer of next-generation pain therapeutics targeting neuronal nitric oxide synthase, has announced encouraging data from its Phase II clinical trial of NXN-188 in patients with migraine.
CoLucid Pharmaceuticals has announced positive Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches. The randomized, double-blind study evaluated 130 migraine patients.
LONDON, Sept. 6 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine.
NeurAxon, Inc., a developer of next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced data from its Phase 2 clinical trial of NXN-188 in patients with migraine.
MOUNTAIN VIEW, Calif., July 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc.
Map Pharmaceuticals has initiated its Phase III clinical program to evaluate MAP0004 as a potential treatment for migraine. This randomized, double-blind, placebo-controlled Phase III trial is designed to evaluate the efficacy and safety of MAP0004 in treating acute migraine.
NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, announced positive Phase I results for NP101, a novel drug-device patch for acute migraine in clinical development.
LA JOLLA, Calif., June 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc.
Merck & Co., Inc.
Neuralieve, a medical technology company pioneering a new approach to treat migraine headache, today reported completion of its clinical trial. The results will be presented June 27 during the annual American Headache Society (AHS) scientific meeting in Boston by Dr. Richard B.
- Emitting flashes of light; glittering.